Synthesis of
NGR peptide
aminopeptidase N receptor (APN/CD13)
gallium-68
positron emission tomography (PET)
radiopharmaceuticals
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
07 Dec 2021
07 Dec 2021
Historique:
received:
05
11
2021
revised:
29
11
2021
accepted:
03
12
2021
entrez:
28
12
2021
pubmed:
29
12
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Tumor hypoxia induces angiogenesis, which is required for tumor cell survival. The aminopeptidase N receptor (APN/CD13) is an excellent marker of angiogenesis since it is overexpressed in angiogenic blood vessels and in tumor cells. Asparagine-glycine-arginine (NGR) peptide analogs bind selectively to the APN/CD13 recepto, therefore, they are important vector molecules in the development of a PET radiotracer which is capable of detecting APN-rich tumors. To investigate the effect of glycosylation and pegylation on in-vivo efficacy of an NGR-based radiotracer, two
Identifiants
pubmed: 34959383
pii: pharmaceutics13122103
doi: 10.3390/pharmaceutics13122103
pmc: PMC8703807
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93
pubmed: 12223276
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188641
pubmed: 34695533
Molecules. 2020 May 14;25(10):
pubmed: 32423178
Eur J Pharm Sci. 2015 Mar 10;69:61-71
pubmed: 25592229
Pharmaceuticals (Basel). 2020 Jul 30;13(8):
pubmed: 32751666
Cancer Res. 2000 Feb 1;60(3):722-7
pubmed: 10676659
Blood. 2008 Oct 1;112(7):2628-35
pubmed: 18574027
Biomed Res Int. 2021 Mar 10;2021:6642973
pubmed: 33778075
Life Sci. 2020 Oct 1;258:118206
pubmed: 32758623
Anticancer Res. 2005 Jul-Aug;25(4):3117-21
pubmed: 16080575
Pharmaceutics. 2021 May 26;13(6):
pubmed: 34073528
Int J Mol Sci. 2016 Apr 14;17(4):565
pubmed: 27089335
Future Oncol. 2018 Jan;14(2):111-122
pubmed: 29072093
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614
Int J Cancer. 1999 May 17;81(4):519-26
pubmed: 10225438
Int J Pharm. 2020 Nov 15;589:119881
pubmed: 32946975
Mol Pharm. 2013 Jan 7;10(1):417-27
pubmed: 23190134
Curr Pharm Biotechnol. 2011 Aug;12(8):1128-34
pubmed: 21470145
Nucl Med Biol. 2014 Mar;41(3):268-75
pubmed: 24438818
Bioorg Med Chem. 2013 Jun 15;21(12):3555-64
pubmed: 23643902
Lancet Oncol. 2018 Jun;19(6):799-811
pubmed: 29753703
Mol Imaging. 2020 Jan-Dec;19:1536012120934957
pubmed: 32862776
J Hematol Oncol. 2015 Dec 21;8:130
pubmed: 26692321
Cell. 1994 Feb 25;76(4):597-8
pubmed: 8124704
J Nucl Med. 2018 Mar;59(3):390-395
pubmed: 29301927
Exp Mol Med. 2012 Jun 30;44(6):387-93
pubmed: 22437631
Circulation. 2005 Mar 29;111(12):1556-66
pubmed: 15795364
J Biol Chem. 1998 May 22;273(21):13047-52
pubmed: 9582341
Cancer Sci. 2011 Mar;102(3):501-8
pubmed: 21205077
Peptides. 2020 Nov;133:170385
pubmed: 32822772
Br J Cancer. 2012 Jun 26;107(1):37-42
pubmed: 22644293
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Bull Cancer. 2010 Feb;97(2):E1-8
pubmed: 20080461
Nat Rev Cancer. 2005 Jan;5(1):29-41
pubmed: 15630413
Oncoimmunology. 2014 Dec 21;3(11):e963406
pubmed: 25941591